



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 51447

**Title:** Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches

**Reviewer's code:** 00209021

**Position:** Editorial Board

**Academic degree:** MD, MSc

**Professional title:** Professor

**Reviewer's country:** Turkey

**Author's country:** United Kingdom

**Reviewer chosen by:** Artificial Intelligence Technique

**Reviewer accepted review:** 2019-09-18 05:06

**Reviewer performed review:** 2019-09-26 04:45

**Review time:** 7 Days and 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The authors undertook a review concerning post-transplantation lymphoproliferative disorders. They should be congratulated for this high quality review. The manuscript is well-written with adequate reference to the current medical literature in the field. The content of the text is satisfactory enough and the figures are informative. The review can be published for educational purposes especially for clinicians in the field after minor revision: -The authors must replace "EPV" with "EBV" in Figure 4.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 51447

**Title:** Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches

**Reviewer's code:** 03317108

**Position:** Peer Reviewer

**Academic degree:** N/A

**Professional title:** Doctor

**Reviewer's country:** China

**Author's country:** United Kingdom

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2019-09-27 12:37

**Reviewer performed review:** 2019-10-07 16:05

**Review time:** 10 Days and 3 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://www.wjgnet.com**

It is a comprehensive and well-written review on Post-transplantation lymphoproliferative disorders (PTLD) covering any aspects of the disease. The discussion on the treatment of PTLD is clear. I would recommend the publication of this manuscript in the journal.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Transplantation

**Manuscript NO:** 51447

**Title:** Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches

**Reviewer's code:** 03291363

**Position:** Editorial Board

**Academic degree:** MBBS, MD

**Professional title:** Doctor, Full Professor, Professor

**Reviewer's country:** Australia

**Author's country:** United Kingdom

**Reviewer chosen by:** Ruo-Yu Ma

**Reviewer accepted review:** 2019-09-27 02:00

**Reviewer performed review:** 2019-10-11 01:51

**Review time:** 13 Days and 23 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

The authors have made an extensive review of the published work in PTLD and have made recommendations about management. My comments are: 1. The study design is not elucidated. Please explain and in particular what statistical analyses were done to determine the adequacy of these studies. Do they have type 1 or type 2 errors for example? 2. Although the authors have recommendations for management some are “hard or established” and some “soft or experimental”. I think it would help the reader if those established principles were listed with the evidence and likewise for the experimental group with evidence. 3. Overall, I suggest that greater emphasis should be placed upon a critical evidence base to evaluate PTLD management. This includes the drugs used (e.g. rituximab), the use of viral load; the use of CSF recovery and other factors 4. The carcinogenic subtype of EBV is critical to PTLD and should be discussed. 5. The authors claim in the introduction that there is “growing incidence of PTLD”: please provide the evidence 6. It should also be made clear that immunosuppression is a risk factor for almost all cancers in transplantation and that those risks can be increased by immunosuppression used to treat primary renal disease before renal transplantation 7. Remove emotional words such as “devastating disorder” 8. Writing style needs some attention: repetition, grammar, meaning of some sentences

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-223-8242  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

- The same title
- Duplicate publication
- Plagiarism
- No